Effectiveness of compression stockings to prevent the post-thrombotic syndrome (the SOX Trial and Bio-SOX biomarker substudy): a randomized controlled trial.
BACKGROUND
Post thrombotic syndrome (PTS) is a burdensome and costly complication of deep venous thrombosis (DVT) that develops in 20-40% of patients within 1-2 years after symptomatic DVT. Affected patients have chronic leg pain and swelling and may develop ulcers. Venous valve disruption from the thrombus itself or thrombus-associated mediators of inflammation is considered to be a key initiating event for the development of venous hypertension that often underlies PTS. As existing treatments for PTS are extremely limited, strategies that focus on preventing the development of PTS in patients with DVT are more likely to be effective and cost-effective in reducing its burden. Elastic compression stockings (ECS) could be helpful in preventing PTS; however, data on their effectiveness are scarce and conflicting.


METHODS
The SOX Trial is a randomized, allocation concealed, double-blind multicenter clinical trial. The objective of the study is to evaluate ECS to prevent PTS. A total of 800 patients with proximal DVT will be randomized to one of 2 treatment groups: ECS or placebo (inactive) stockings worn on the DVT-affected leg daily for 2 years. The primary outcome is the incidence of PTS during follow-up. Secondary outcomes are severity of PTS, venous thromboembolism (VTE) recurrence, death from VTE, quality of life and cost-effectiveness. Outcomes will be evaluated during 6 clinic visits and 2 telephone follow ups. At baseline, 1 and 6 months, blood samples will be obtained to evaluate the role of inflammatory mediators and genetic markers of thrombophilia in the development of PTS (Bio-SOX substudy).


CONCLUSIONS
The SOX Trial will be the largest study and the first with a placebo control to evaluate the effectiveness of ECS to prevent PTS. It is designed to provide definitive data on the effects of ECS on the occurrence and severity of PTS, as well as DVT recurrence, cost-effectiveness and quality of life. This study will also prospectively evaluate the predictive role of biomarkers that are reflective of putative underlying pathophysiological mechanisms in the development of clinical PTS. As such, our results will impact directly on the care of patients with DVT.


BACKGROUND
NCT00143598 and ISRCTN71334751.
Kahn
Susan R
SR
Centre for Clinical Epidemiology and Community Studies, Jewish General Hospital, Montreal, Quebec, Canada. susan.kahn@mcgill.ca
Shbaklo
Hadia
H
Shapiro
Stan
S
Wells
Philip S
PS
Kovacs
Michael J
MJ
Rodger
Marc A
MA
Anderson
David R
DR
Ginsberg
Jeffrey S
JS
Johri
Mira
M
Tagalakis
Vicky
V
D004311:Double-Blind Method; D006801:Humans; D011186:Postphlebitic Syndrome / Q000517:prevention & control*; D012107:Research Design; D053828:Stockings, Compression; D020246:Venous Thrombosis / Q000628:therapy*
Thromb Haemost. 2000 Jan;83(1):10-3
10669146
Lancet. 1998 Feb 21;351(9102):571-2
9492784
Cochrane Database Syst Rev. 2000;(3):CD000265
10908469
N Engl J Med. 2000 Aug 17;343(7):457-62
10950667
Clin Orthop Relat Res. 2001 Feb;(383):197-203
11210954
Ann Intern Med. 2001 Jul 17;135(2):98-107
11453709
Ann Intern Med. 2001 Sep 4;135(5):367-73
11529700
Arch Intern Med. 2001 Sep 24;161(17):2105-9
11570939
Chest. 2001 Dec;120(6):1964-71
11742929
Thromb Haemost. 2002 Jan;87(1):7-12
11848459
J Vasc Surg. 2002 Apr;35(4):701-6
11932666
Thromb Haemost. 2002 Jul;88(1):162-3
12152661
Curr Opin Hematol. 2002 Sep;9(5):437-42
12172463
Blood. 2003 Feb 15;101(4):1243-8
12393393
J Vasc Surg. 2003 Feb;37(2):410-9
12563215
Thromb Haemost. 2003 Feb;89(2):284-7
12574808
Circulation. 2003 Jun 17;107(23 Suppl 1):I9-16
12814980
Arch Intern Med. 2004 Jan 12;164(1):17-26
14718318
Curr Opin Hematol. 2004 May;11(3):192-7
15257020
Ann Intern Med. 2004 Aug 17;141(4):249-56
15313740
Ann Intern Med. 2004 Aug 17;141(4):314-5
15313748
Chest. 2004 Sep;126(3 Suppl):338S-400S
15383478
Chest. 2004 Sep;126(3 Suppl):401S-428S
15383479
Br J Surg. 1980 Aug;67(8):569-72
7427048
JAMA. 1983 Jan 14;249(2):242-3
6848811
J Cardiovasc Surg (Torino). 1986 Jan-Feb;27(1):5-16
3511065
Arch Intern Med. 1988 Oct;148(10):2131-8
3052345
Arch Intern Med. 1989 Jul;149(7):1651-2
2742439
Arch Intern Med. 1989 Oct;149(10):2255-7
2679475
JAMA. 1990 May 23-30;263(20):2753-9
2332918
Arch Intern Med. 1998 Mar 23;158(6):585-93
9521222
J Vasc Surg. 1998 Nov;28(5):848-54
9808852
CMAJ. 1999 May 4;160(9):1303-6
10333832
J Vasc Surg. 1999 Jun;29(6):1071-6
10359941
Thromb Haemost. 1999 May;81(5):680-3
10365736
Int Angiol. 1999 Jun;18(2):83-102
10424364
J Thromb Haemost. 2005 Apr;3(4):718-23
15733061
Thromb Haemost. 2005 Aug;94(2):362-5
16113826
J Thromb Haemost. 2005 Dec;3(12):2671-6
16359506
Br J Haematol. 2006 Aug;134(4):357-65
16822286
J Clin Epidemiol. 2006 Oct;59(10):1049-56
16980144
N Engl J Med. 2006 Oct 26;355(17):1780-9
17065639
N Engl J Med. 1990 Jun 7;322(23):1622-7
2188129
Arch Intern Med. 1991 May;151(5):933-8
2025141
J Vasc Surg. 1992 Feb;15(2):377-82; discussion 383-4
1735898
Acta Radiol. 1992 Jul;33(4):297-300
1633039
Blood. 1993 Jul 15;82(2):513-20
8329706
Arch Intern Med. 1994 Jan 24;154(2):164-8
8285811
Stat Med. 1994 Jul 15-30;13(13-14):1341-52; discussion 1353-6
7973215
Blood. 1995 Feb 1;85(3):607-14
7833465
Circulation. 1996 Jan 1;93(1):74-9
8616945
Ann Intern Med. 1996 Jul 1;125(1):1-7
8644983
Blood. 1996 Nov 15;88(10):3698-703
8916933
Ann Intern Med. 1997 Mar 15;126(6):454-7
9072931
N Engl J Med. 1997 Apr 3;336(14):973-9
9077376
Lancet. 1997 Mar 15;349(9054):759-62
9074574
Med Decis Making. 1997 Apr-Jun;17(2):123-5
9107606
Med Decis Making. 1997 Apr-Jun;17(2):126-35
9107607
Med Decis Making. 1997 Apr-Jun;17(2):142-51
9107609
Cardiovasc Surg. 1997 Feb;5(1):6-15
9158116
Thromb Haemost. 1997 May;77(5):825-8
9184386
J Gen Intern Med. 1997 Jun;12(6):374-83
9192256
Blood. 1997 Sep 1;90(5):1747-50
9292507
Br J Haematol. 2000 Jun;109(3):519-22
10886197